Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vanda Pharmaceuticals's Enterprise Value is €148.2 Mil.
Vanda Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-122.5 Mil. Therefore, Vanda Pharmaceuticals's EV-to-OCF for today is -1.21.
The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-OCF or its related term are showing as below:
FRA:VM4'
s EV-to-OCF Range Over the Past 10 Years
Min: -378.59 Med: 3.65 Max: 134.13
Current: -1.28
During the past 13 years, the highest EV-to-OCF of Vanda Pharmaceuticals was 134.13. The lowest was -378.59. And the median was 3.65.
FRA:VM4's EV-to-OCF is ranked worse than 63.14% of 1408
companies
in the Biotechnology industry
Industry Median: -3.715
vs FRA:VM4: -1.28
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vanda Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vanda Pharmaceuticals's share price for today is €4.548.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.977.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's EV-to-OCF falls into.
Vanda Pharmaceuticals's current Enterprise Value is €148.2 Mil.
Vanda Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-122.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (FRA:VM4) has a EV-to-OCF of -1.21 as of Aug. 29, 2026. According to the industry distribution chart, Vanda Pharmaceuticals ranks #889 out of 1408 companies in the Biotechnology industry, placing it in the top 63.1%.
Is Vanda Pharmaceuticals' EV-to-OCF too high?
Vanda Pharmaceuticals' current EV-to-OCF is -1.21. Based on the distribution chart, Vanda Pharmaceuticals ranks #889 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vanda Pharmaceuticals has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' EV-to-OCF compare to LYEL and ZNTL?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #889 out of 1408 companies for EV-to-OCF. This places Vanda Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vanda Pharmaceuticals's current EV-to-OCF is -1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (FRA:VM4) is currently considered Fairly Valued. The stock's GF Value™ is €4.48, compared to a current price of €4.55 — trading 1.5% above its estimated fair value. The current EV-to-OCF is -1.21. Vanda Pharmaceuticals' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vanda Pharmaceuticals (FRA:VM4), the current EV-to-OCF is -1.21 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (FRA:VM4) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued.
The current stock price of €4.55 is trading 1.5% above its estimated GF Value™ of €4.48.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:VM4:
EV-to-OCF: -1.21
GF Value™: €4.48 vs. price of €4.55 (1.5% above fair value)
No single metric tells the full story. See the FRA:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
63GF Score
Get the complete analysis for FRA:VM4
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VM4 has been successfully added to your 
